Practical syntheses of DOTAGA-DBCO and DFO-DBCO, strained alkyne pre-cursors to radioimmunoconjugates for targeted alpha therapy
- Bioorg Med Chem. 2022 Nov 1:73:117010. doi: 10.1016/j.bmc.2022.117010.
- 1. Janssen Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States. Electronic address: [email protected].
- 2. Janssen Research & Development L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States.
We describe practical methods to prepare DOTAGA-DBCO and DFO-DBCO from commercially available starting Materials. DOTAGA-DBCO is available in five steps from cyclen with a 33 % overall yield at gram scale. Our synthesis of DFO-DBCO also proceeds in five steps from commercially available starting Materials. These bifunctional molecules possess chelating functionality for the binding of medically important radiometals and a strained alkyne suitable for Huisgen cyclization with an azide. These syntheses represent an important step toward improved radioimmunoconjugates for imaging and therapeutic applications.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer